Revance Therapeutics, Inc., a Newark, California-based biopharmaceutical company that has developed proprietary platform technology which enables local, targeted delivery of large macromolecules across skin, closed a $45m financing.
The round was led by Essex Woodlands Health Ventures and NovaQuest Capital, with participation from CNF Investments, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Pac-Link Ventures and Essex Capital Corporation.
Led by President and CEO Dan Browne, Revance develops its topical and injectable neuromodulation pipeline in both aesthetic and therapeutic categories.
The company intends to use the new capital to continue further late-stage development to its lead investigational product, RT001 Botulinum Toxin Type A Topical Gel, which has demonstrated safety and statistically significant efficacy in Phase 2 clinical trials.
In conjunction with the funding, Jonathan Tunnicliffe, Partner at NovaQuest, will join Revance’s Board of Directors.